SEC Form 4 · accession 0001123292-17-001480
Recro Pharma, Inc. · REPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Geraldine Henwood
Officer — President and CEO · Director
Period of report
Sep 28, 2017
Accepted (ET)
Oct 2, 2017 · 6:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001588972
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 28, 2017 | M | 31,100 | — | A | 135,600 | D | |
| Common Stock | Sep 28, 2017 | F | 9,794 | $9.04 | D | 125,806 | D | |
| Common Stock | holding | — | — | — | 50,000 | I | By spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On September 28, 2017, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to 31,100 performance-based restricted stock units, which were converted into 31,100 shares of common stock on a one-for-one basis.